Loading market information…
ASX · PER.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 04:57 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Percheron Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 70.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Percheron Therapeutics Limited’s next earnings report is currently expected on Feb 24, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Percheron Therapeutics Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Percheron Therapeutics Limited, an Australian enterprise established in 2000 with its headquarters in Melbourne, is dedicated to the research and development of groundbreaking antisense pharmaceuticals. Formerly known as Antisense Therapeutics Limited until its name change in December 2023, the company holds a promising product portfolio. This includes ATL1102, an antisense inhibitor designed to target CD49d, which is currently undergoing Phase IIa clinical trials for the treatment of various inflammatory and muscular conditions such as Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, and asthma. Another key asset is Atesidorsen (ATL1103), an oligonucleotide that has finished Phase II clinical trials. Atesidorsen functions by blocking the growth hormone receptor, aiming to lower blood concentrations of insulin-like growth factor-I (IGF-I) and thereby address illnesses linked to an overabundance of growth hormone activity.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| A$493.38K |
| Q4 2022 | Aug 31, 2022 | -A$0.00+60.0% vs estimate | A$0.00 |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
